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Abstract
DOG1 is an established diagnostic marker for gastrointestinal stromal tumours (GIST), but has been reported in salivary gland 
tumours (SGT) as an acinar and intercalated duct marker. However, its speciicity and distribution is not well established. 
The aim of this study was to evaluate the diagnostic utility of DOG-1 expression in SGT in addition to comparing it with 
myoepithelial markers. Normal salivary tissue and SGT (n = 184) were examined for expression of DOG1 and a range of 
myoepithelial markers. SGT included: acinic cell carcinoma (ACC, n = 15), secretory carcinoma (SC, n = 9), pleomorphic 
adenoma (PA, n = 49), carcinoma ex-PA (Ca ex-PA, n = 11), adenoid cystic carcinoma (AdCC, n = 20), polymorphous adeno-
carcinoma (PAC, n = 6), myoepithelioma (n = 6), myoepithelial carcinoma (MC, n = 2), basal cell adenoma (BCA, n = 14), 
canalicular adenoma (CA, n = 19), mucoepidermoid carcinoma (MEC, n = 11), oncocytoma (n = 2), adenocarcinoma NOS 
(AdNOS, n = 4), basal cell adenocarcinoma (BCAC, n = 2), salivary duct carcinoma (SDC, n = 3) and papillary cystadeno-
carcinoma (PCAC, n = 1). Normal acini and ACC (14/15) showed strong luminal DOG1 staining; SC were largely negative 
with only focal expression in 3/9 cases. Luminal staining was seen in PA (14/49), PAC (4/6), Ca ex-PA (4/11) and AdCC 
(6/20). 8/11 MEC showed luminal and/or mucous cell staining. No staining was seen in myoepithelioma, MC, CA, adNOS 
and BCAC. BCA showed strong staining of myoepithelial cells in some cases (5/14). Variable myoepithelial DOG1 staining 
was seen in PA, Ca ex PA, BCA, SDC and PCAC which was not as consistent as myoepithelial markers such as calponin, p63 
and αSMA. Absence of DOG1 can diferentiate ACC from SC, but staining is variable in PA, PLGA and Ca ex-PA. Myoepi-
thelial staining in some tumours but not in normal gland suggests a wider distribution in SGT than originally envisaged.
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Introduction
Diagnosing salivary gland tumours can be challenging due 
to the heterogeneity of the cellular diferentiation, morpho-
genesis and histological patterns. Many diferent tumour 
entities share similar histological patterns, which further 
complicates diagnosis.
In 2004, ‘Discovered on GIST-1’ (DOG1) was shown to 
be highly expressed in a high proportion of gastrointestinal 
stromal tumours (GISTs) [1–3]. Subsequently, a number of 
in vivo studies revealed DOG1 to be a calcium activated 
chloride channel expressed on secretory epithelium in mouse 
models [4, 5]. More recently, DOG1 expression has been 
reported in salivary gland tumours [6–8], in particular, as 
a marker for acinic and intercalated duct cells. Some stud-
ies have suggested that the DOG1 protein may be essential 
for salivary gland secretion with a possible role in salivary 
gland tumourigenesis [5, 9]. However, its pattern of expres-
sion and speciicity in a range of tumours has not been fully 
established. Strong staining is seen at the luminal aspect of 
acinar cells in normal glands, and luminal staining has been 
shown in the acini in ACC [10], and in small ductal struc-
tures in PAC and epithelial myoepithelial carcinoma (EMC) 
[6]. Luminal and abluminal staining has been described in 
BCA and AdCC [6, 11]. Our clinical experience has shown 
expression by myoepithelial cells in some instances, a ind-
ing not reported to date.
The aim of this study was to study the expression pattern, 
speciicity and diagnostic potential of DOG-1 in salivary 
gland tumours.
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Methods
Normal parotid and submandibular gland tissue and SGT 
(n = 184) were examined for expression of DOG1 and 
a range of myoepithelial and cytokeratin markers using 
immunohistochemistry (IHC) on cases retrieved from the 
department archive. These included acinic cell carcinoma 
(ACC, n = 15), secretory carcinoma (SC, n = 9), pleomorphic 
adenoma (PA, n = 49), carcinoma ex-PA (Ca ex-PA, n = 11), 
adenoid cystic carcinoma (AdCC, n = 20), polymorphous 
adenocarcinoma (PAC, n = 6), myoepithelioma (n = 6), 
myoepithelial carcinoma (MC, n = 2), basal cell adenoma 
(BCA, n = 14), canalicular adenoma (CA, n = 19), mucoep-
idermoid carcinoma (MEC, n = 11), oncocytoma (n = 2), 
adenocarcinoma NOS (AdNOS, n = 4), basal cell adenocar-
cinoma (BCAC, n = 2), salivary duct carcinoma (SDC, n = 3) 
and a papillary cystadenocarcinoma (PCAC, n = 1).
The diagnosis of the cases was conirmed by H&E stain-
ing and examination under the light microscope. Tumours 
were classiied according to WHO 2017 guidelines [12] and 
current literature. FISH analysis for the ETV6 rearrange-
ment was used as a gold standard for the diagnosis of all 
included SC.
Immunohistochemistry
IHC for DOG1 was performed on the entire cohort. For com-
parison a range of other ‘myoepithelial markers’ were also 
studied in a proportion of tumours including S100, αSMA, 
p63, calponin and CK14 as previously described [8]. Multi-
ple pilot assays were undertaken to determine the optimum 
dilution and conditions (Table 1).
4 µ thick sections from formalin-ixed, parain embed-
ded tissue blocks were used for IHC staining. Sections were 
deparainised in xylene followed by incubation in ethanol 
for 5 min each. Endogenous peroxidase was blocked by incu-
bation in 3% methanolic  H2O2 blocking solution for 20 min 
followed by a wash in phosphate bufered saline (PBS). 
Antigen retrieval was carried out by placing the slides in a 
heat-resistant plastic container illed with citrate or EDTA 
bufer solution in a microwave for 10 min on high power. 
The slides were left to cool for 2 min, placed in PBS to 
avoid dehydration and blocked with 100% normal serum 
for 30 min at room temperature (RT). Serum was removed 
followed by addition of the primary antibody overnight at 
4 °C in a humidiied chamber. Omission of primary antibody 
served as the negative control.
After overnight incubation, unbound primary antibody 
was removed and the slides washed twice for 5 min with 
PBS. The secondary antibody and ABC solution were pre-
pared according to the manufacturer’s instruction (Vec-
tastain Elite kits, Vector Laboratories, Burlingame USA). 
Sections were covered with secondary antibody for 30 min 
followed by two washes in PBS and addition of avidin biotin 
complex (ABC) solution for 30 min at RT. After two further 
washes in PBS 3,3ƍ-diaminobenzidine (DAB, Vector labo-
ratories) was applied to the sections for 5–8 min and the 
colouring reaction stopped using distilled water. Sections 
were counterstained with Mayer’s haematoxylin, mounted 
in DPX mounting media and left to dry at RT.
IHC staining was assessed subjectively under standard 
light microscopy, taking into account the pattern and locali-
sation of the staining. Stained sections were photographed 
using a digital imaging system (cell^D) and a digital camera 
attached to a light microscope (Olympus, UK). As previ-
ously described, myoepithelial staining was considered posi-
tive in the correct morphologic context to ensure exclusion 
of stromal cells [8].
Results
DOG‑1
Strong apical/luminal DOG1 staining was seen in normal 
acini (10/10) (Fig. 1a), although occasional cells demon-
strated lateral and basal expression. Staining was stronger 
in serous acini compared to mucous and focally interca-
lated ducts showed positive luminal reactivity. A similar 
staining pattern was seen in ACC, with widespread lumi-
nal DOG1 staining in 14 of the 15 cases (Fig. 1b). SC how-
ever were largely negative (Fig. 1c) with only weak focal 
luminal staining in three cases with a microcystic archi-
tecture (3/9) (Fig. 1d). SC with a papillary cystic architec-
ture or clear cell change were negative. Variable luminal 
Table 1  Details of primary 
antibodies used in the study
Antibody Clonality Dilution Retrieval Supplier
DOG 1 Mouse monoclonal 1:250 EDTA Dako®, Cambridgeshire, UK
S100 Rabbit polyclonal 1:2,000 EDTA Dako®, Cambridgeshire, UK
SMA Mouse monoclonal 1:75 Citrate Dako®, Cambridgeshire, UK
P63 Mouse monoclonal 1:25 EDTA Dako®, Cambridgeshire, UK
CK 14 Mouse monoclonal 1:20 Citrate Abcam®, Cambridge, UK
Calponin Rabbit monoclonal 1:100 Citrate EP798Y, Abcam®, Cambridge, UK
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staining was seen in PA (14/49) (Fig. 1d), PAC (4/6—not 
shown), Ca ex-PA (4/11) (Fig. 1i), AdCC (6/20) (Fig. 1e). 
MEC showed luminal and/or mucous cell staining in 8/11 
cases (Fig. 1f). BCA showed strong staining of myoepi-
thelial cells in 5/14 cases (Fig. 1h), and some myoepithe-
lial staining was also seen in PA, Ca ex PA, BCA, SDC, 
AdCC and PCAC (Fig. 1; Table 2). No staining was seen 
in myoepitheliomas (0/6), MC (0/2), CA (0/19), AdNOS 
(0/4) and BCAC (0/2).
Myoepithelial DOG-1 staining was compared with a 
range of existing markers including αSMA, calponin, p63, 
S100 and CK14.
α‑Smooth Muscle Actin (αSMA)
Widespread αSMA staining was seen in myoepithelial cells 
surrounding the acini in normal salivary glands. The major-
ity of the ACC and SC were negative for αSMA with focal 
staining seen in only 4/14 and 3/9 of cases. More consist-
ent myoepithelial staining was seen in PA, Ca ex PA and 
myoepithelioma whereas PAC was negative.
Strong αSMA staining was also seen in abluminal cells of 
both tubular and cribriform AdCC (17/20 cases) consistent 
with myoepithelial cells. The three negative cases included 
two solid and one tubular AdCC.
Almost all cases of PAC were αSMA negative (not 
shown) whereas all basal cell adenomas demonstrated strong 
αSMA staining in the abluminal, myoepithelial cells. How-
ever, areas lacking αSMA expression were also observed.
Calponin
ACCs and SC did not stain for calponin. Staining was seen 
in most cases of pleomorphic adenoma (44/47; 93.6%) 
(Fig. 2a). Staining was frequently observed in abluminal 
and spindled myoepithelial cells whereas plasmacytoid 
cells were always negative. Similar to PA, 90% (9/10) of Ca 
ex-PA showed Calponin staining in abluminal cells in addi-
tion to scattered stromal cells (Fig. 2b). Calponin staining 
was seen in myoepithelial cells in 66.7% of myoepitheliomas 
(4/6) (Fig. 2c). Focal staining was seen in myoepithelial car-
cinomas whereas PAC were largely negative with only one 
case showing some focal staining (Fig. 2d).
Calponin staining was seen in 16/20 (80%) AdCC with 
expression in myoepithelial cells in both cribriform (Fig. 2e) 
and tubular (Fig. 3f) variants whereas the three negative 
cases had solid and mixed patterns.
CK14
In normal salivary glands, CK 14 staining was seen in 
myoepithelial cells surrounding acini and ducts (Fig. 3a). 
Both ACC and SC were largely negative for CK14; however 
4/16 ACC showed focal CK14 staining (Fig. 3b) with difuse 
staining seen in one SC (Fig. 3c).
For PA, 89.6% (43/48) of the cases were CK14 positive 
with staining of both ductal and myoepithelial cells. How-
ever, staining was weak or absent in plasmacytoid cells, and 
cells in myxochondroid areas (Fig. 3d). CK 14 was difusely 
positive in 90.9% of Ca-ex-PA (10/11) with strong staining 
in myoepithelial and abluminal cells throughout the tumours 
(Fig. 3e).
Fig. 1  Representative photomicrographs showing DOG-1 staining 
pattern in a normal gland; b acinic cell CA; c secretory carcinoma—
negative; d secretory carcinoma—focal positive, e pleomorphic ade-
noma; f adenoid cystic CA; g mucoepidermoid carcinoma; h basal 
cell adenoma; i carcinoma in pleomorphic adenoma; j papillary cys-
tadenocarcinoma. g Solid arrow—mucous cells, dotted arrow—inter-
mediate cells, double arrow—luminal spaces with DOG1 positivity
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In myoepithelioma, CK14 was variably positive in myoep-
ithelial cells in 5/6 of the cases (83.3%), mainly in cells with 
spindled morphology (Fig. 3f). Both cases of myoepithelial 
carcinoma showed focal staining of the tumour cells (Fig. 3g).
Table 2  Summary of DOG1 
staining in salivary gland 
neoplasms
For each tumour type the total number of positive cases is given in relation to the total number of the cases
Site Cases +ve Pattern
Normal gland 10 10/10 Acini & ducts—luminal
Acinic cell carcinoma 15 14/15 Difuse luminal in acini and small ducts
Secretory carcinoma 9 3/9 Negative or weak/focal luminal in microcystic areas
Pleomorphic adenoma 49 14/49 Focal luminal or myoepithelial (5/14)
Ca ex PA 11 4/11 Luminal and/or myoepithelial cells (2/4)
Myoepithelioma 6 0/6 N/A
Myoepithelial carcinoma 2 0/2 N/A
Adenoid cystic carcinoma 20 6/20 Weak abluminal + luminal
Polymorphous adenocarcinoma 6 4/6 Focal luminal
Basal cell adenoma 14 5/14 Luminal or abluminal/myoepithelial—variable (5/5)
Canalicular adenoma 19 0/19 N/A
Mucoepidermoid carcinoma 11 8/11 Luminal + mucous cell brush borders
Oncocytoma 2 0/2 N/A
Adenocarcinoma NOS 4 0/4 N/A
Basal cell adenocarcinoma 2 0/2 N/A
Salivary duct carcinoma 3 1/3 Myoepithelial cells (1/1)
Papillary cystadenocarcinoma 1 1/1 Abluminal/myoepithelial cells (1/1)
Total 184 70
Fig. 2  Calponin staining in a pleomorphic adenoma, b Ca ex-pleo-
morphic adenoma, c myoepithelioma and d PAC. Staining was pre-
dominantly seen in myoepithelial cells surrounding the ductal areas 
in (a, b). In c, scattered staining in spindle cells was seen throughout. 
PAC were negative except with one case showing focal staining. d 
Calponin staining highlighting the abluminal/myoepithelial cells Cri-
briform AdCC and e tubular AdCC (original magniication ×20)
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CK 14 staining in AdCC was observed in 13 out of 14 
examined cases with strong difuse staining in both lumi-
nal and abluminal cells (Fig. 3h). Variable reactivity of 
the tumour cells was seen in the tubular variant which also 
showed weaker staining intensity compared to tumours 
with a cribriform pattern. The only negative AdCC case 
had a solid architecture.
All cases of PAC showed difuse CK14 staining. The 
staining was strong and difuse throughout tumour cells 
(Fig. 3i). The variable expression proile of CK14 between 
diferent tumours indicates that it is not a reliable or spe-
ciic myoepithelial marker.
S100
Difuse S100 staining was seen in myoepithelial cells in 
normal glands. Some ACC showed weak focal staining 
in acini, however most were negative. Cases with solid 
and papillary cystic patterns were completely negative for 
S100.
All cases of SC (9/9) were S100 positive and showed 
strong and diffuse staining of nuclei and cytoplasm of 
tumour cells (Fig. 4a). All PA (44/44; 100%) showed dif-
fuse S100 staining including in spindle and plasmacytoid 
myoepithelial cells as well as cells within myxoid tissue 
(Fig. 4b). All cases of Ca-ex-PA (11/11) showed similar 
reactivity (Fig. 4c).
Fig. 3  CK14 staining in salivary gland tumours a in normal tissue 
CK14 staining was mainly seen as a cytoplasmic staining of myoepi-
thelial cells surrounding acini and in some basal cell in ducts, b 
CK14 in ACC was variable with one case showing difuse ablumi-
nal staining, c CK14 in one SC with difuse cytoplasmic staining 
of abluminal cells, d CK14 staining in PA was predominantly seen 
in the cytoplasm of most tumour cells, but plasmacytoid cells were 
negative, e CK14 expression in CA ex-PA was mainly seen in the 
cytoplasm of the abluminal type cells, f CK14 staining in myoepithe-
lioma was variably positive in the cytoplasm of the neoplastic myoep-
ithelial cells, mainly spindle cells, g CK14 staining in MC was focal 
with cytoplasmic staining of scattered tumour cells, i CK14 staining 
in AdCC (cribriform variant) and j PAC—difuse staining was seen 
throughout the tumour (original magniication ×20)
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There was strong and diffuse S100 reactivity in all 
myoepitheliomas (6/6) and myoepithelial carcinomas (2/2) 
including spindled and plasmacytoid cells (Fig. 4d, e). All 
examined cases of AdCC (14/14) were positive for S100. 
Staining was observed mainly in the luminal cells of the 
ducts or cystic structures in the tubular and cribriform cases 
with some showing both luminal and abluminal staining. 
Difuse staining was seen in the solid variant, but with less 
intensity. All ive cases of PAC (100%) were positive for 
S100, with all the neoplastic cells showing difuse strong to 
moderate cytoplasmic staining (Fig. 4f).
p63
In ACC, 14/16 (87.5%) of the examined cases were p63 
negative, with only two cases showing focal staining. Stain-
ing in SC was also variable with only 3/9 cases showing p63 
positivity (not shown).
44/49 cases of PA (89.8%) showed p63 staining in ablu-
minal and myoepithelial cells. Ca-ex-pleomorphic adenoma 
showed a similar staining distribution, pattern and intensity 
in 90.9% (10/11) of the cases. 100% of myoepitheliomas 
(6/6) showed strong nuclear staining in spindle and plas-
macytoid cells. However, only one case of myoepithelial 
carcinoma (1/2) was positive, with focal areas of nuclear 
staining of the tumour cells.
In AdCC, 9/12 (75%) of the cases were p63 positive 
mainly in the abluminal cells, whereas luminal cells in 
ductal and tubular areas were negative. The negative cases 
showed a mostly solid pattern. All cases of PAC and BCA 
showed p63 staining in abluminal cells with stronger and 
more widespread staining seen in BCA.
Comparison with other myoepithelial markers showed 
that all cases with DOG-1 staining in myoepithelial cells 
were also positive for αSMA, calponin, CK14 and p63. In 
addition, only a limited number of PA, Ca ex PA and AdCC 
showed abluminal and/or myoepithelial DOG-1 positivity 
compared to other markers.
Discussion
DOG‑1 Expression
DOG1 has been reported as a marker for diferentiated acinic 
cells and intercalated duct cells [6], and is thought to be 
particularly useful for the diagnosis of ACC. In the current 
study, we examined a wide range of salivary neoplasms to 
determine the expression proile and distribution of DOG1 
and report expression in myoepithelial cells for the irst time.
ACC showed difuse luminal DOG1 staining in 14/15 
(93.3%) of the examined cases in agreement with the lit-
erature and similar to the staining pattern seen in the acini 
Fig. 4  S100 staining in salivary gland tumours. a Nuclear and cyto-
plasmic staining in myoepithelial cells in PA whereas luminal cells 
were largely negative, b S100 expression in Ca ex-PA with difuse 
staining in the cytoplasm of luminal, abluminal and scattered stromal 
cells, c myoepithelioma showing difuse cytoplasmic S100 staining 
in the neoplastic spindle cells, d S100 staining in MC with strong 
cytoplasmic staining in the plasmacytoid cells, e PAC showed difuse 
staining in almost all the tumour cells (original magniication ×20)
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of normal glands [6, 7, 10, 11, 13–17]. Staining of duct 
cells was patchy and weak but widespread luminal stain-
ing was evident in all tumours. The majority of SC lacked 
DOG1 staining, similar to previous reports [6–8, 15, 18], 
conirming the diagnostic usefulness of DOG-1 in difer-
entiating between ACC and SC.
28% of pleomorphic adenomas showed some DOG-1 
staining with a predominantly apical/luminal pattern as 
previously reported [6, 17]. However, staining in myoepi-
thelial cells was seen in 5 cases, which is a novel inding. 
A similar pattern was seen in carcinoma ex PA with apical/
luminal staining in addition to myoepithelial staining in 
two cases whereas no staining was evident in myoepithe-
liomas or myoepithelial carcinomas.
Only two cases of AdCC showed weak focal reactivity 
for DOG-1. The irst had a tubular pattern with DOG1 
staining of the luminal aspect of the tubules, while the 
second showed a mixture of solid and cribriform patterns 
with occasional cells staining towards the periphery of the 
solid tumour islands. These are somewhat diferent to pre-
vious indings [6, 19] which reported consistent luminal 
staining within the cribriform areas. The reason for this 
diference is not entirely clear but lack of DOG1 staining 
in AdCC and diference between antibody clones has been 
reported by other groups [17].
Expression of DOG1 in PAC was only seen in two of 
ive cases and showed only focal luminal expression simi-
lar to a previous report [6]. Somewhat similar to our ind-
ings, Montalli et al. reported cytoplasmic DOG1 staining 
in a 4/21 PACs in their cohort with cytoplasmic or occa-
sionally apical staining [11].
Five cases of basal cell adenoma showed strong and 
difuse staining for DOG1 in abluminal cells, which was 
similar to the pattern of αSMA and p63 staining, and was 
consistent with strong expression of DOG-1 on myoepi-
thelial cells. Luminal staining was also seen focally in two 
cases. Montalli et al. suggested that staining was luminal 
in tubular and abluminal in non-tubular BCAs but we did 
not observe an obvious correlation between histological 
and staining patterns [20]. However, our BCA cohort was 
smaller including solid, tubular and non-tubular variants 
making it diicult to establish a relationship between mor-
phology and staining.
MEC showed focal staining for DOG1 in 8 cases. In 3 
this was weak luminal staining, and in the remainder there 
was weak or faint expression at the margins of mucous cells. 
This is somewhat similar to a previous study reporting weak 
staining in mucous and intermediate cells in MEC [19]. Can-
berk et al. studied FNAs from salivary tumours reporting 
DOG-1 cytoplasmic staining in 14% of cases but did not 
describe the precise location of the staining [17]. Myoepi-
thelial staining for DOG1 was also seen in one adenocarci-
noma NOS and a papillary cyst adenocarcinoma.
Expression of Myoepithelial Markers
Calponin appeared to the most specific and sensitive 
myoepithelial marker followed by αSMA and p63. In some 
AdCC, PA and BCA, DOG-1 variable staining in myoepi-
thelial cells was seen. ACC and SC were largely negative 
for myoepithelial markers similar to previous reports [7, 
21–23]. S100 was very useful in diferentiating between 
these two entities as strong difuse S100 staining was seen 
in all SC but ACC were negative except for occasional 
focal and weak staining. This supports previous reports 
in the literature [7, 14, 24–27] and further conirms the 
diagnostic usefulness of S100 in SC [8].
αSMA was expressed in the majority of PA in ablu-
minal and myoepithelial cells whereas plasmacytoid cells 
were negative [28, 29]. Calponin staining was present in 
all analysed cases including plasmacytoid cells indicating 
higher sensitivity than αSMA [30]. Abluminal/myoepithe-
lial staining for S100 and p63 was also seen in all cases 
and similar proile was exhibited by Ca ex-PA [26, 31, 32]. 
αSMA, calponin and p63 staining in AdCC was variable, 
but was mainly seen in myoepithelial cells surrounding 
tubular and cribriform structures [33, 34]. Almost all cases 
demonstrated difuse luminal and abluminal staining for 
CK14, suggesting a lack of speciicity. In PAC, staining 
for αSMA and calponin were largely negative, but difuse 
CK14 and S100 staining was seen in most tumour cells 
[35, 36] whereas p63 staining was limited to abluminal 
cells [37].
Conclusion
Absence of luminal DOG-1 staining can diferentiate ACC 
from SC, but variable staining is seen in PA, PLGA and Ca 
ex-PA. Myoepithelial staining in some tumours but not in 
normal gland is an interesting inding suggesting a wider 
distribution in SGT than originally envisaged. However, 
DOG-1 staining in myoepithelial cells appears inconsistent 
and not as reliable and sensitive as the existing markers, 
limiting its diagnostic utility.
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